Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus
19 October 2016
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that in its Phase 1 dose-escalation study, ganaxolone intravenous (IV) achieved dose levels targeted for efficacy in patients with status epilepticus (SE) and other indications. Status epilepticus is a life-threatening medical emergency associated with high mortality and limited treatments. Typically, single or combination IV antiepileptic drugs are used in an attempt to break the seizures, however there are approximately 45,000 patients in the U.S. who do not respond to first-line treatment.
Chairman highlights 2016 industry highlights at OIS
19 October 2016
The past year has seen a number of important approvals and promising study progress in both biotechnology and ophthalmic devices, Emmett T. Cunningham Jr., MD, PhD, MPH, told the more than 900 attendees at the Ophthalmology Innovation Summit in his “Chairman’s 2016 Year in Review.”
Liquid biopsy open database created under Cancer Moonshot, as pharma joins the fray
19 October 2016
Twenty stakeholders, including major biopharmas, diagnostic players and academic institutions, have committed to creating what they expect will be the largest liquid biopsy open database for cancer genomic profiling data. It’s part of the broader ongoing Cancer Moonshot effort led by U.S. Vice President Joe Biden.
White House To Announce Big Push For Cancer Blood Tests
19 October 2016
The White House, as part of the Cancer Moonshot effort being run by Vice President Joe Biden, is announcing a major push to develop blood tests that can detect and monitor cancer, that aims to unite makers of diagnostic tests, drugs, and other cancer-related products.
New report highlights impact of intellectual property on U.S. economy
18 October 2016
In late September, the U.S. Department of Commerce released a comprehensive report that found intellectual property (IP) intensive industries contribute more than $6 trillion (38.2 percent) to U.S. gross domestic product (GDP). What’s more, IP-intensive industries are the source – directly or indirectly – of 45 million jobs, roughly 30 percent of all the jobs in the United States.
Novosibirsk scientists can now decisively deal with cancerous stem cells
18 October 2016
Specialists at the Novosibirsk-based Institute of Cytology and Genetics in Siberia have discovered what they call a universal marker for cancerous stem cells, and have developed a method of destroying such cells, which has reportedly led to successful treatment of two different malignant tumors in lab mice.
European biopharma funding is down 43% so far this year
17 October 2016
Funding for European biopharmaceutical companies is down 43 percent for the first three quarters of 2016 compared with the same period last year, with total equity investment dropping to $2.335 million from $4.119 million.
With St. Pete super-crystal, new drugs could become easier to develop
17 October 2016
Researchers at St. Petersburg-based ITMO University have put together an optically active nanodimensional super-crystal with unusual architecture that is believed to enable the separation of organic molecules. This is expected to help simplify new drug development technology considerably. The results of the research have been published in English in Scientific Reports.
Russian browser to brace your immune system
17 October 2016
Researchers at the Institute of Bioorganic Chemistry in Moscow have developed a multifunctional browser, designated VDJviz, to process big data derived from modern DNA sequence analysis. The project is expected to step up the development of immunogenomics. The results of the research have been described in detail in English in BMC Genomics.
Biotech IPOs slow in Q3 despite improvement in general markets
14 October 2016
Biotech IPOs were sluggish in the third quarter, with only seven companies successfully completing their offerings on U.S. exchanges, raising a collective $396 million in the process, according to BioWorld analysis. That was 42 percent below the 12 biotech IPOs, raising $1.35 billion in the third quarter last year and 36 percent off the 11 companies completing their offerings in the second quarter this year, raising $564 million.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024
CRISPR technologies fuelling haematological innovations
17 April 2024
17 April 2024